USA – Moffitt Cancer Center and Fulgent Pharma, a nanobiotechnology company, have forged a strategic partnership to advance cancer treatment through collaborative efforts in clinical development and preclinical co-development initiatives.

This collaboration merges Moffitt’s clinical capabilities with Fulgent’s nanotherapeutics and genomics platforms to accelerate personalized cancer therapies. 

With priority access to Moffitt’s expertise and resources, Fulgent aims to expedite its clinical pipeline, enhancing patient screening and data sharing to deliver investigational therapies quicker.

“Fulgent Pharma, a leader in nanoencapsulation technology, has transformed paclitaxel, a chemotherapy drug known for its poor solubility, into a soluble counterpart suitable for intravenous injection called FID-007,” said a representative from Fulgent Pharma.

“This partnership aligns with Moffitt’s mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients,” said Moffitt President and CEO Patrick Hwu, M.D.

“This initiative aims to revolutionize cancer therapeutics, creating tailored treatments to meet individual patient needs,” said a spokesperson from the collaboration.

Moffitt Cancer Center, renowned for cancer treatment and research, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc., have announced a strategic partnership to advance cancer treatment through clinical development and preclinical co-development initiatives. 

With priority access to Moffitt’s expertise and resources, Fulgent aims to expedite its clinical pipeline, enhancing patient screening and data sharing to deliver investigational therapies quicker. 

Fulgent Pharma’s transformation of paclitaxel into a soluble counterpart, FID-007, has shown promising tumor reduction in Phase 1 trials across various cancers. 

Last month, Moffitt Cancer Center joined forces with NVIDIA, Oracle, and Deloitte to launch an innovative initiative to revolutionize cancer care delivery through state-of-the-art A.I. and machine learning technologies. 

The initiative commences with the refinement of a comprehensive language model, utilizing extensive clinical notes from Moffitt to enhance billing coding processes and ensure precision in clinical documentation. 

Deloitte will contribute to model training and project execution, capitalizing on Moffitt’s private Oracle Cloud Infrastructure A.I. and NVIDIA NeMo. 

The overarching objective is to enhance clinical quality, streamline medical coding, facilitate patient matching for clinical trials, and propel advancements in cancer research.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook